Congo: Ebola drugs trail shows ‘90% survival rate’
In the Democratic Republic of Congo, four drugs were trialed on patients suffering from Ebola virus.
Reportedly, two of those were considerably more effective in treating the disease, the study found.
The drugs, named REGN-EB3 and mAb114, work by attacking the Ebola virus with antibodies, neutralizing its impact on human cells.
According to health officials, the trailed drugs will now be used to treat all Ebola patients in DR Congo.
The US National Institute of Allergy and Infectious Diseases (NIAID), which co-sponsored the trial, said the results are "very good news" for the fight against Ebola.
REGN-EB3 and mAb114 were developed using antibodies harvested from survivors of Ebola, which has killed more than 1,800 people in DR Congo in the past year.